Novo Nordisk
Active· since May 19, 2026
- 121
- days running
- 0
- relaunches
- 27,598
- EU reach
Ad copy
HF’s unanswered questions, investigated like never before. The POSEIDON study is a global investigation, assembling real‑world evidence from 18,000+ patients across 18 countries. Findings put the global impact of CV inflammation in HF on record.1
Dive Deep into the evidence online
LEARN MORE🪄Crush AI
Like this ad? Make it yours.
Crush rebuilds this exact creative around your product — your brand, your colors, your offer — in about a minute.
